Semax vs ACTH: Why the Peptide Should Not Be Treated as ACTH

Semax vs ACTH is a comparison between a synthetic seven-amino-acid ACTH-derived peptide and the endogenous 39-amino-acid adrenocorticotropic hormone. Semax retains only ACTH residues 4 through 7 and then continues with Pro-Gly-Pro, whereas intact ACTH contains the complete melanocortin sequence required for its classical adrenal endocrine pharmacology. Their shared four-residue segment establishes research lineage, not molecular, receptor, endocrine, pharmacokinetic, or clinical equivalence.

Keeping Semax separate from its parent-hormone lineage is essential in Semax Research. ACTH studies can explain why particular sequences were chosen during peptide design, but they should not be used automatically as evidence for Semax exposure, receptor activity, hormonal effects, safety, or clinical outcomes.

Research-use notice for the Semax vs ACTH comparison: InStrips products are intended for laboratory research and analytical characterization. Structural relationships between Semax and adrenocorticotropic hormone do not imply that either research material is intended to diagnose, treat, cure, or prevent disease, injury, deficiency, absorption disorders, digestive conditions, or any other medical condition.

ACTH and Semax Differ First in Size

Human ACTH contains 39 amino-acid residues.

Semax contains seven.

Therefore, Semax contains less than one fifth of the residue count of intact ACTH.

Only Four Residues Are Directly Shared Through the Design

Semax retains the ACTH sequence:

Met4-Glu5-His6-Phe7

These become residues 1 through 4 in Semax.

The Remaining Three Semax Residues Are Not ACTH(8-10)

After Phe, intact ACTH continues:

Arg-Trp-Gly

through positions 8 to 10.

Semax instead continues:

Pro-Gly-Pro

This Makes Semax an Analog Rather Than a Simple ACTH Fragment

A pure fragment reproduces a continuous sequence from the parent molecule.

ACTH(4-7) is such a fragment.

Semax extends that fragment using a different sequence.

Calling Semax “ACTH(4-10)” Is Therefore Chemically Inaccurate

ACTH(4-10) is:

MEHFRWG

Semax is:

MEHFPGP

Three of seven residues differ.

Why Some Papers Call Semax an ACTH(4-10) Analog

This terminology describes the historical design relationship.

Both peptides occupy a seven-residue window beginning with ACTH residue 4, but the C-terminal three residues were redesigned in Semax.

The Classical Melanocortin Motif Is Altered

ACTH contains the sequence:

His-Phe-Arg-Trp

at residues 6 through 9.

This HFRW motif is central to classical melanocortin-receptor recognition.

Semax Contains Only His-Phe From That Four-Residue Motif

Its corresponding sequence is:

His-Phe-Pro-Gly

This replacement changes receptor-recognition chemistry substantially.

Semax Should Not Automatically Inherit ACTH Receptor Pharmacology

Sequence ancestry can provide a reason to investigate a receptor.

It cannot substitute for compound-specific:

• binding assays
• functional assays
• antagonist studies
• receptor-selectivity measurements

ACTH Has a Well-Defined Endocrine Function

Endogenous ACTH is an important signal in the hypothalamic-pituitary-adrenal axis.

It is released from pituitary corticotroph cells and acts prominently on the adrenal cortex.

MC2R Is Central to ACTH Endocrine Pharmacology

The melanocortin 2 receptor is strongly associated with adrenal ACTH signalling.

Activation contributes to adrenal steroidogenic responses.

Semax Was Designed to Separate From Classical ACTH Hormonal Activity

The Semax research programme arose from ACTH-fragment work aimed at investigating regulatory and central effects without simply reproducing the full endocrine hormone.

Therefore “ACTH-Like” Needs Qualification

Semax is ACTH-like in a narrow structural sense:

it contains ACTH residues 4 through 7.

It is not ACTH-like in the sense of containing the complete 39-residue hormone.

ACTH Is Produced Endogenously

ACTH arises from proopiomelanocortin processing in pituitary corticotroph cells.

Its production is regulated by endocrine signalling.

Semax Does Not Arise From Normal POMC Processing

The sequence MEHFPGP is not the product generated when human POMC is processed through the classical ACTH pathway.

Semax is prepared synthetically.

This Creates Different Biological Origins

ACTH participates in an endogenous feedback system involving:

• hypothalamic signals
• pituitary secretion
• adrenal responses
• glucocorticoid feedback

An externally supplied synthetic Semax preparation follows the experimental protocol instead.

ACTH Secretion Is Pulsatile and Circadian

Endogenous ACTH concentration changes according to:

• time of day
• stress
• feedback signalling
• pulsatile pituitary secretion

Synthetic Semax Exposure Does Not Reproduce This Secretion Pattern

A research administration has a route, concentration, and timing defined externally rather than by pituitary physiology.

ACTH and Semax Also Have Different Degradation Problems

The 39-residue hormone presents many peptide bonds and recognition sites to metabolic enzymes.

Semax is a short proline-rich heptapeptide engineered specifically with a PGP C terminus.

One Molecule's Half-Life Cannot Be Assigned to the Other

Pharmacokinetic characteristics depend on:

• molecular size
• sequence
• enzymatic cleavage
• route
• distribution

ACTH Pharmacokinetics Are Not Semax Pharmacokinetics

Even if both peptides share MEHF, the majority of their molecular structures differ.

ACTH Metabolites Are Also Not Automatically Semax Metabolites

Because Semax ends with PGP, it can generate glyproline-containing fragments that do not arise from intact ACTH at the same sequence position.

ACTH Endocrine Tests Should Not Be Used as Semax Identity Tests

An adrenal response to ACTH is a functional endocrine assay.

It cannot establish whether an unknown sample contains Semax.

Semax Identity Should Be Established Chemically

Analytical characterization can include:

• molecular mass
• sequence-specific fragmentation
• chromatographic retention
• purity

ACTH and Semax Have Very Different Molecular Masses

The difference in residue count creates a large difference in total molecular mass.

They can therefore be distinguished readily by suitable analytical methods.

The Four Shared Residues Do Not Create Analytical Ambiguity for the Intact Molecules

An assay designed specifically for the full sequence can distinguish ACTH from Semax.

Less specific antibodies against a shared fragment may require more careful validation.

Immunoreactivity Can Be Misleading Without Epitope Information

An antibody recognizing an ACTH fragment might potentially respond to related peptides containing part of that epitope.

Researchers should know:

• which sequence the antibody recognizes
• its cross-reactivity
• which molecular forms are present

ACTH Clinical Evidence Does Not Transfer to Semax

ACTH-related medicines have their own clinical and regulatory history.

That evidence should not establish Semax:

• effectiveness
• safety
• dosage
• indications

Semax Clinical Literature Must Be Evaluated Separately

Semax has its own geographically concentrated clinical literature, particularly from Russia and related research settings.

Those studies should be evaluated according to their:

• design
• sample size
• comparator
• endpoint
• publication accessibility

An ACTH Indication Is Not a Semax Indication

Even when two peptides are structurally related, clinical indications follow direct evidence and regulatory evaluation rather than sequence ancestry.

Semax Should Not Be Treated as an Adrenal-Stimulation Peptide by Default

Its origin from ACTH does not establish that the intended or dominant experimental response is adrenal steroidogenesis.

The modified melanocortin sequence provides a strong reason to avoid that assumption.

Likewise, Semax Findings Should Not Be Used to Redefine ACTH

A neural or gene-expression finding involving Semax does not establish that full ACTH produces the same response under the same conditions.

Shared Ancestry Works in Neither Direction as Evidence Transfer

ACTH findings remain ACTH findings.

Semax findings remain Semax findings.

ACTH(4-7) Findings Need Their Own Label Too

The isolated MEHF tetrapeptide lacks:

• the remaining ACTH sequence
• the PGP extension

It represents a third molecular condition.

ACTH(4-10) Is a Fourth Condition

MEHFRWG is structurally closer to Semax than full ACTH, but it is still a different peptide.

PGP Is a Fifth Condition

Pro-Gly-Pro is only the Semax C-terminal tripeptide.

Its research findings should not be presented as though the intact ACTH-derived N terminus were present.

A Useful Semax-ACTH Comparison Table Needs Exact Molecule Names

Researchers can distinguish:

• ACTH(1-39)
• ACTH(1-24)
• ACTH(4-10)
• ACTH(4-7)
• Semax
• PGP

This Prevents “Peptide Family” Evidence Inflation

Grouping all ACTH-related sequences together can make the Semax evidence base appear much larger than the compound-specific literature actually is.

Receptor Family Similarity Should Also Be Kept Separate

Melanocortin receptors include several subtypes.

A response involving one receptor subtype cannot automatically characterize all ACTH-derived peptides.

Neural Effects Are Not Proof of Classical Melanocortin Signalling

Semax has been investigated in relation to:

• BDNF-associated transcription
• monoamine systems
• gene-expression patterns
• ischemia-associated models

These observations do not independently identify the primary molecular receptor responsible.

Mechanism Should Be Demonstrated, Not Inherited

ACTH ancestry can guide hypotheses.

Compound-specific experiments must test them.

Semax Is Registered as Its Own Substance in FDA Chemical Databases

FDA's substance-registration system lists Semax as the defined ingredient substance Met-Glu-His-Phe-Pro-Gly-Pro and maps ACTH(4-7)-Pro-Gly-Pro as a synonym.

A substance registry establishes chemical identity, not approval or therapeutic effectiveness.

A Regulatory Substance Record Is Not an Approved-Drug Record

This distinction is especially important for research peptides.

A chemical can have:

• a UNII
• a CAS number
• a database entry

without being an FDA-approved drug.

FDA Has Explicitly Distinguished Semax From Approved Drugs

Recent FDA review of Semax-related bulk drug substances states that Semax free base and Semax acetate are not components of FDA-approved drug products.

This U.S. regulatory fact should be separated from clinical or regulatory history in other countries.

Jurisdiction Matters

A compound can have:

• research history in one country
• clinical use in another
• no comparable authorization elsewhere

Global claims should therefore specify the regulator being discussed.

The ACTH Relationship Does Not Alter U.S. Regulatory Status

Semax cannot inherit the approval status of ACTH-related medicines merely because it contains four ACTH residues.

Likewise, ACTH Safety Information Does Not Define Semax Safety

Differences in sequence, route, exposure, and receptor interactions require compound-specific safety evidence.

The Same Applies to Contraindications

Contraindications established for one ACTH preparation cannot be transferred mechanically to Semax, nor can their absence establish Semax safety.

“Semax Is ACTH” Creates Multiple Scientific Errors at Once

It incorrectly merges:

• molecular identity
• endogenous origin
• receptor pharmacology
• pharmacokinetics
• endocrine function
• clinical evidence

A Better Description Preserves Both Relationship and Difference

Semax can be described as:

a synthetic ACTH(4-7)-PGP heptapeptide developed from ACTH-fragment research.

This wording acknowledges lineage without implying equivalence.

The Evidence Boundary Becomes Even More Important With “Therapy” Language

Once Semax is discussed as a broad treatment category, regional clinical studies, animal mechanisms, online product claims, and regulatory status can become blurred.

This issue is examined in Why “Semax Therapy” Is Broader Than the Current Research Evidence.

Reading the Foundational Design Literature

The PubMed-indexed review A Nootropic Adrenocorticotropin Analog 4-10-Semax: 15 Years Experience in Its Design and Study places Semax directly within the history of ACTH-fragment analogue development and describes the research programme that distinguished the synthetic peptide from intact ACTH.

The historical review contains claims arising from the research and clinical literature available in that setting and period. Those claims should be evaluated according to their individual study designs rather than treated as evidence that Semax and ACTH are pharmacologically or clinically interchangeable.

Final Perspective

Semax and ACTH share only a short four-residue sequence, Met-Glu-His-Phe, while differing dramatically in peptide length, remaining sequence, melanocortin pharmacophore, biological origin, degradation, endocrine context, and evidence base.

Semax is therefore appropriately described as ACTH derived, but not as ACTH itself. Its PGP extension deliberately changes the region that would otherwise contain ACTH residues Arg-Trp-Gly and disrupts the complete HFRW melanocortin motif.

Research conclusions should follow the exact molecule tested and should not use ACTH receptor pharmacology, clinical use, regulatory status, dosage information, or safety evidence as substitutes for direct Semax evidence.